retatrutide obesity triple hormone receptor agonist Eli Lilly and Company's agonist, retatrutide, successful in two additional phase 3 trials, delivering significant improvements in weight and A1C retatrutide triple hormone receptor agonist
Pay in 4 interest-free payments of $5.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16


























